These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 31433337)

  • 21. Olanzapine: a review of rapid and long-acting parenteral formulations.
    Owen RT
    Drugs Today (Barc); 2010 Mar; 46(3):173-81. PubMed ID: 20467591
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olanzapine long-acting injection: a review of first experiences of post-injection delirium/sedation syndrome in routine clinical practice.
    Bushe CJ; Falk D; Anand E; Casillas M; Perrin E; Chhabra-Khanna R; Detke HC
    BMC Psychiatry; 2015 Apr; 15():65. PubMed ID: 25886006
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Olanzapine pamoate: a stick in time? A review of the efficacy and safety profile of a new depot formulation of a second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Jan; 63(1):140-50. PubMed ID: 18834452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug safety evaluation of olanzapine pamoate.
    Schöttle D; Kuhnigk O; Naber D
    Expert Opin Drug Saf; 2013 Nov; 12(6):897-903. PubMed ID: 24024627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine pamoate for the treatment of schizophrenia.
    Naber D
    Expert Opin Pharmacother; 2011 Mar; 12(4):627-33. PubMed ID: 21254860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Case of Olanzapine-Induced Fever.
    Yang CH; Chen YY
    Psychopharmacol Bull; 2017 Jan; 47(1):45-47. PubMed ID: 28138204
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit of extending the dosing interval of olanzapine on schizophrenics during maintenance treatment.
    Suzuki H; Hibino H; Inoue Y; Mikami A; Matsumoto H; Mikami K
    Asian J Psychiatr; 2017 Dec; 30():100-101. PubMed ID: 28858761
    [No Abstract]   [Full Text] [Related]  

  • 28. Olanzapine-induced and Risperidone-induced Leukopenia: A Case of Synergistic Adverse Reaction?
    Woon LS; Tee CK; Gan LLY; Deang KT; Chan LF
    J Psychiatr Pract; 2018 Mar; 24(2):121-124. PubMed ID: 29509183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Delirium with dystonia: a variant of neuroleptic malignant syndrome?
    Dowling JJ; Patrick V
    Am J Psychiatry; 1989 Feb; 146(2):276-7. PubMed ID: 2563212
    [No Abstract]   [Full Text] [Related]  

  • 30. Olanzapine pamoate for the treatment of schizophrenia--a safety evaluation.
    Samalin L; Garay R; Ameg A; Llorca PM
    Expert Opin Drug Saf; 2016; 15(3):403-11. PubMed ID: 26761429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety study.
    Jones ME; Andrews JS; Faries DE; Landry J; Xu J; Detke HC; Chhabra-Khanna R; McDonnell DP
    BMC Psychiatry; 2015 Nov; 15():278. PubMed ID: 26567159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Necrotizing Pancreatitis Associated With Orally Disintegrating Formulation of Olanzapine: Implications on Clinical Presentation and Management.
    Vaidyanathan S; Subramanian K; Bharadwaj B; Das S; Kola GST; Maroju NK
    J Clin Psychopharmacol; 2019; 39(5):519-521. PubMed ID: 31433336
    [No Abstract]   [Full Text] [Related]  

  • 33. Olanzapine-induced neuroleptic malignant syndrome.
    Burkhard PR; Vingerhoets FJ; Alberque C; Landis T
    Arch Gen Psychiatry; 1999 Jan; 56(1):101-2. PubMed ID: 9892264
    [No Abstract]   [Full Text] [Related]  

  • 34. Dysphagia From Long-Term Olanzapine Use: A Rare Adverse Effect.
    Idiculla PS; Siddiqui JH
    J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):600-601. PubMed ID: 34321404
    [No Abstract]   [Full Text] [Related]  

  • 35. [Treatment with haloperidol of clozapine-triggered drug-induced delirium].
    Spisla C; Bünter M
    Psychiatr Prax; 1997 Nov; 24(6):308. PubMed ID: 9490450
    [No Abstract]   [Full Text] [Related]  

  • 36. Case report: possible neuroleptic malignant syndrome associated with olanzapine.
    Moltz DA; Coeytaux RR
    J Clin Psychopharmacol; 1998 Dec; 18(6):485-6. PubMed ID: 9864084
    [No Abstract]   [Full Text] [Related]  

  • 37. Tardive dystonia associated with olanzapine therapy.
    Gunal DI; Onultan O; Afsar N; Aktan S
    Neurol Sci; 2001 Aug; 22(4):331-2. PubMed ID: 11808858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Case report of withdrawal syndrome after olanzapine discontinuation.
    Nayudu SK; Scheftner WA
    J Clin Psychopharmacol; 2000 Aug; 20(4):489-90. PubMed ID: 10917413
    [No Abstract]   [Full Text] [Related]  

  • 39. Delirium with visual hallucinations induced by low-dose olanzapine.
    Takeuchi N; Makino T; Nishihara M
    Psychogeriatrics; 2022 May; 22(3):415-416. PubMed ID: 35274396
    [No Abstract]   [Full Text] [Related]  

  • 40. Can olanzapine cause delirium in the elderly?
    Lim CJ; Trevino C; Tampi RR
    Ann Pharmacother; 2006 Jan; 40(1):135-8. PubMed ID: 16368923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.